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Abstract 
The Central Indiana Beacon Community leads efforts for improving adherence to oral hypoglycemic agents (OHA) 
to achieve improvements in glycemic control for patients with type 2 diabetes.  In this study, we explored how OHA 
adherence affected hemoglobin A1C (HbA1c) level in different racial groups.  OHA adherence was measured by 6-
month proportion of days covered (PDC).  Of 3,976 eligible subjects, 12,874 pairs of 6-month PDC and HbA1c 
levels were formed between 2002 and 2008.  The average HbA1c levels were 7.4% for African-Americans and 6.5% 
for Whites.  The average 6-month PDCs were 40% for African-Americans and 50% for Whites. In mixed effect 
generalized linear regression analyses, OHA adherence was inversely correlated with HbA1c level for both African-
Americans (-0.80, p<0.0001) and Whites (-0.53, p<0.0001).  The coefficient was -0.26 (p<0.0001) for the 
interaction of 6-month PDC and African-Americans.  Significant risk factors for OHA non-adherence were race, 
young age, non-commercial insurance, newly-treated status, and polypharmacy.  
 
BACKGROUND 
 
Non-adherence to oral hypoglycemic agents (OHA) is an important risk factor for suboptimal glycemic control and 
for both high morbidity and mortality rates among patients with type 2 diabetes.1-2  It is estimated that non-
adherence to medications is as high as 60% among patients with type 2 diabetes and many patients do not adhere to 
their medication after the first six months of therapy.3  In addition, information about rates of medication adherence 
are usually not available to providers in clinical practice and few interventions have attempted to improve 
medication adherence for diabetic patients.4-5  
 
Recently, major organizations have called for quality improvement interventions aimed at increasing medication 
adherence.6  However, assessing medication adherence through patient self-report is difficult and measures of 
adherence based on claims records are subject to a number of potential biases.7-9 Moreover, it is hard to collect and 
deliver the information to the provider when it is of the most use: at the time of the clinical encounter.  Health 
information technology (HIT) and health information exchange (HIE), which support key components of chronic 
disease management including diabetes, may be useful in this regard.10-11     However, very few HIT/HIE systems 
have been applied to either documenting or intervening in medication adherence.  A recent study reported that, 
among more than 7,000 articles about HIT interventions, only 13 had described HIT components on medication 
adherence.5  Boosting health data infrastructure and HIT that support medication adherence interventions should be 
a high priority for health care reform.12 
 
HIE and HIT systems have good potential to establish integrated and multifaceted intervention strategies to improve 
medication adherence in several domains.13-14  First, the rich health information and data integration of the HIE can 
generate aggregated, complete, and longitudinal patient data across different health care facilities over time.  If 
complete, patient medication history generated from an HIE could ensure an accurate data-driven medication 
adherence measure.  Second, a computerized clinical decision support system (CDSS) could inexpensively remind 
providers or patients in routine care about medication refills, and perhaps could predict risk factors for medication 
non-adherence and thereby provide recommendations for overcoming barriers to adherence. Third, the nature of 
multidirectional communication in the HIE could allow adherence data to be shared among physicians, pharmacists, 
and care managers, and thus support the interactions needed for good care coordination.  Fourth, widespread HIE 
connectivity could ensure monitoring and following up of patient adherence over time.  In addition, the ability of an 
HIE to communicate adherence patterns to patients could encourage better patient engagement in medication-taking 
behavior.15-18   
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The American Recovery and Reinvestment Act promotes HIT/HIE innovations to achieve meaningful, measurable 
improvement in health care quality, safety, and efficiency in selected Beacon Communities.19  The Central Indiana 
Beacon Community (CIBC) leads efforts to increase medication adherence to improve diabetic patients’ glycemic 
and lipid control.  Using clinical data captured from various sources, the CIBC will measure patient adherence and 
deliver this information to providers through our local well-established HIE infrastructure.20  In order to document 
medication adherence issues in type 2 patients and to demonstrate their impact,  we conducted two studies, using 
HIE data, showing that medication adherence to OHA and antihyperlipidemic agents are significantly associated 
with measurable health outcomes.21-22 In order to better target these interventions, we explored a variety of patient 
factors that might be associated with glycemic control. The relationships of race, medication adherence, and 
subsequent glycemic control are inconsistent in previous different studies.23-24 
 
The primary objective was to determine if medication adherence could be assessed using HIE, analyze how patterns 
of OHA adherence differ among racial groups, and the subsequent impact on glycemic control. The secondary 
objective was to identify the risk factors for OHA non-adherence.  This study would provide valuable information in 
identifying patients at high risk of medication non-adherence and suboptimal glycemic control, in order to further 
construct patient-specific interventions in a rich HIE/HIT environment. 
 
METHODS 
 
Data sources and settings 
The setting for this retrospective study is the Indiana Network of Patient Care (INPC) which is an operational 
regional HIE of now more than 60 hospitals and more than 100 geographically distributed clinics that has served 
Indianapolis for more than fifteen years.  This system mediates medical record and claims data from hospitals, 
laboratories, imaging centers, pharmacies, and physician offices. Information includes registration records, 
laboratory tests, radiology reports, diagnoses, and administrative data.25  Medical records in the INPC are linked at 
the patient level through a robust linking algorithm. Medication dispensing records typically include medication 
refill dates, days of supply, dose, and frequency.  Environmental factors (at the county level), such as median 
household income, adult obesity rate, and adult diabetes rate were obtained from publicly accessible US Department 
of Agriculture (USDA) data and were mapped to each patient by county information.  Patient identifiers were 
removed before data analysis, in order to protect the study participants’ confidentiality.  This study was approved by 
the Institutional Review Board of Indiana University and the INPC management committee.   
 
Eligibility Criteria 
The study cohort was selected from patients whose data are contained in the INPC system.  To be included, subjects 
had to be 18 years or older during the study period January 1, 2002 through December 31, 2008.  They were either 
African-Americans or Whites and were diagnosed as having type 2 diabetes based on International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes of 250.X0 and 250.X2. These type 2 patients 
were additionally confirmed by their OHA history, according to the First Databank Standard Therapeutic Code 
(STC: 71) for OHAs: Biguanides, Sulfonylurea (SU), Thiazolidinedione (TZD) and other OHAs (Meglitinides and 
α-glucosidase) during the study period.  Since the focus of this study was OHA use, patients who used insulin (STC: 
0177) were excluded.  To be included in the cohort, the patient had to have at least one HbA1c test result from the 
INPC and at least one pharmacy claim for an OHA six months prior to the HbA1c test date. (Figure 1) 
 
Measurements 
Patient OHA medication adherence was calculated using a standard measurement: proportion of days covered 
(PDC).  The PDC is the medication adherence measurement used by the Pharmacy Quality Assurance project 
conducted by the National Committee for Quality Assurance (NCQA).26 The PDC focuses on persistence or 
continuation at the time of prescribed treatment.  It is defined as the total number of medication covered days 
divided by the number of days in a certain time period.  Claims data, including refill date, days of supply, dosage, 
and frequency are used to calculate PDC.27   For patients who took multiple OHAs, we calculated the combined 
average 6-month PDC grouped by each OHA therapeutic class.  OHA medication adherence was used as the 
independent variable in the analysis of its association with HbA1c control.  It was also used as the dependent 
variable in a secondary analysis about predictors of OHA adherence.  In the secondary analysis, OHA adherence 
was classified into two levels: 1) adherence to OHA if the 6-month PDC was equal to or greater than 80%; and 2) 
non-adherence to OHA if the 6-month PDC was less than 80%. 
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Patients HbA1c levels were retrieved from the INPC using a set of standard laboratory test terminologies that were 
mapped to the LOINC® codes 17855-8, 17856-6 and 8548-4. The HbA1c test date was defined as the index date, 
and we calculated the PDC for a 6-month period before each HbA1c laboratory test result for each patient.  The 
patient’s HbA1c level was used as the dependent variable in the primary analysis.  
 
 
Figure 1.  Patient selection 
We studied several patient demographic, clinical, and health environmental characteristics which may influence 
HbA1c control and OHA adherence.  The predictor selections were based on previous Type 2 diabetes management 
studies.28-29  We extracted patient demographic information such as age, gender, and race.  Clinical characteristics 
included duration of OHA treatment, the number of HbA1c tests, and the number of concurrent OHA medications.  
The prescribed OHA drug classes included Biguanides, Sulfonylureas, Thiazolidinediones, other OHAs, and 
multiple classes.  Selected common health environmental factors (at the county level) included adult diabetes rates, 
adult obese rate, recreation and fitness facilities per 1,000 population, median household income, and metropolitan 
status.  These factors were analyzed as predictors for both HbA1c control and OHA adherence.   
 
Statistical Analysis 
Descriptive statistics of patient characteristics, OHA adherence, and average HbA1c levels were reported for black 
and white patients. Continuous variables were compared using t-tests and categorical variables were compared using 
χ2 tests. 
 
We examined the associations between glycemic control and OHA adherence using mixed effect generalized linear 
regression models. Regression coefficients were used to quantify the associations between covariates and HbA1c 
control.  Random subject effects were used in these models to accommodate the potential associations among 
observations contributed by the same study subjects.  Stratified analyses by race were conducted to assess the 
relationship between covariates and HbA1c in black and white patients.  Combined models including medication 
adherence (6 month PDC), races, and their interaction were used to examine the potentially differential effects of 
medication adherence in patients of difference races.   
 
Secondarily, we explored predictors of medication adherence. In this analysis, we used dichotomized adherence 
outcomes. Odds ratios (OR) were used to quantify the magnitude of associations between potential predictors and 
3,976 patients were African-Americans or Whites 
108,184 had claims indicating treatment by OHA (STC* code=71) 
194,274 Type 2 diabetes patients identified by ICD-9 (250.X0 or 250.X2) and 
were 18-64 years old during 2002 to 2008 
71,426 dispensed OHA only 
36,758 excluded because of 
insulin use (STC code=0177) 
5,175 have at least one OHA prescription prior to HbA1c test date 
10,208 have at least one HbA1c test result from the INPC 
35,146 linked to the INPC by hospital number 
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OHA adherence.  All analyses were implemented using SAS 9.1 (SAS Institute, Gary, North Carolina).  P values 
less than 0.05 were considered significant.  
 
RESULTS 
 
Patients’ Characteristics 
 A total of 3,976 subjects (21% African-American and 79% White) met all inclusion and exclusion criteria. A total 
of 12,784 pairs of 6-month PDC and HbA1c level were formed across the study period.  Patient demographic and 
clinical characteristics grouped by race are outlined in Table 1.  Compared with White patients, African-American 
patients were younger (48 vs. 51), more female (65% vs. 51%), and a higher percentage proportion had non-
commercial insurance (40% vs. 17%). African-Americans had higher average HbA1c levels (7.4% vs. 6.8%), a 
higher proportion of patients with uncontrolled HbA1c levels (48% vs. 35%), and a slightly higher average number 
of HbA1c tests (4.2 vs. 3.7).  On the other hand, the African-American population had a lower average 6-month 
PDC (40% vs.50%) and a lower proportion of patients with optimal OHA adherence (21% vs. 33%).  Other patient 
factors, such as the age distribution, duration of treatment, number of concurrent OHA medications and OHA 
medication classes were similar among the two racial groups.   
 
Table 1.  Patient demographic and clinical characteristics by race 
* Data are mean (95% CI).  All values are statistically significant at p < 0.001. 
 
Among the selected environmental health factors (at the county level), African-Americans had lower median 
household income ($44,957 ± 6,367 vs. $52,297 ± 12,534) and higher rate of metropolitan resident (99% vs. 91%).  
Statistics for other factors were not significantly different between African-Americans and Whites: adult diabetes 
rate (8.94 ± 0.34 vs. 8.85 ± 0.77), adult obesity rate (28.46 ± 0.65 vs. 28.38 ± 1.28), and recreation and fitness 
facilities per 1,000 population (0.14 ± 0.01 vs. 0.10 ± 0.03).  
 
 
    African-American                  White  
   Number (Percentage)   Number (Percentage)  
Number of Subject 834 (20.9%) 3,142 (79.1%)  
Demographics   
           Age at study entry (year) *       48.65 (48.0, 49.0)        51.04  (50.72, 51.36)  
18-30 34 (4.1%) 90 (2.8%)  
31-40 131 (15.7%) 341 (10.8%)  
41-50 279 (33.5%) 851 (27.1%)  
>51 390 (46.7%) 1,860 (59.2%)  
           Female gender 553 (65.2%) 1,171 (54.0%)  
           Non-commercial  insurance 343 (40.5%) 525 (16.6%)  
Clinical Characteristics  
           A1C Level (%) *         7.38  (7.26, 7.50)    6.85  (6.81, 6.91)  
           A1C <7% 440 (51.9%) 2,056 (64.9%)  
           Number of A1C test *       4.15 (4.03, 4.26)   3.76  (3.70, 3.83)  
           OHA  6-month PDC *       40% (39%, 43%)     50%  (49%, 51%)  
           OHA  6-month PDC ≥ 80% 177 (21.2%) 1,031 (32.8%)  
           Duration of OHA treatment (Year)   
0-3 696 (83.5%) 2,693 (85.7%)  
3-6 133 (15.9%) 441 (14.0%)  
6-9 5 (0.6%) 8 (0.3%)  
           Number of concurrent OHA medications   
1 593 (71.1%) 2,155 (68.6%)  
2 198 (23.7%) 802 (25.5%)  
≥ 3 43 5.2%) 185 (5.9%)  
           OHA medication classes   
Biguanide  Only 314 (37.4%) 1,316 (42.1%)  
Sulfonylurea Only 173 (20.6%) 358 (11.1%)  
           Thiazolidinedione Only 41 (4.9%) 206 (6.6%)  
Other 7 (0.8%) 38 (1.2%)  
Multiple classes 304 (36.2%) 1,205 (38.6%)  
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Effects of OHA adherence and patient factors on HbA1c control 
Table 2 summarizes the results of the mixed model that analyzed effects of OHA adherence and patient factors on 
HbA1c control.  OHA adherence is significantly inversely correlated with patient HbA1c level: the coefficients were 
-0.80 (p<0.0001) for African-Americans, -0.53 (p<0.0001) for Whites, and -0.49 (p<0.0001) for the entire cohort.  
Other factors that were significantly inversely correlated with HbA1c level for all three models include non-
commercial insurance, number of HbA1c tests, and number of concurrent OHA medications.  Patients who were 
treated with multiple OHA classes had significantly higher HbA1c levels than patients who were treated with a 
single OHA class.  In the combined model, African-Americans had higher HbA1c levels (0.55, p<0.0001); however, 
the coefficient for HbA1c and the interaction of the 6-month PDC and African-American race was -0.26 (p<0.0001).  
Patient age, duration of OHA treatment, and metropolitan status had no effects on HbA1c control.  Environmental 
factors at the county level also were not significantly associated with HbA1c control (data not shown).  
 
Table 2. Association between A1C level and patient factors 
^ p-value >0.05 
p-value for other coefficients are smaller than 0.0001 
 
Predictors of OHA adherence 
Nine predictors of adherence are shown in Table 3. Six of them achieved statistical significance (p<0.001).  Three 
negative predictors were African-American race (OR: 0.61), non-commercial insurance (OR: 0.62), and number of 
concurrent OHA medications (OR: 0.80).  Positive predictors were age (OR: 1.32), number of A1C tests (OR: 1.10), 
and duration of OHA treatment (OR: 1.19).  Patients treated with OHA monotherapy have significantly higher 6-
month PDCs than patients treated by polypharmacy.  Gender and metropolitan status had no effects on OHA 
medication adherence.  
 
DISCUSSION 
 
The primary purpose of this study was to determine whether medication adherence could be assessed using an HIE 
system and determine if there were racial differences that impacted glycemic control.  We found significant 
differences in both OHA adherence and HbA1c control between African-Americans and Whites. The African-
American population had a 10% lower average OHA adherence and a 0.5% higher HbA1c level.  We additionally 
confirmed that OHA adherence is significantly and inversely associated with HbA1c levels.  More interestingly, the 
larger magnitude of the slope of this relationship for African-Americans means that African-Americans who become 
compliant achieve the same level of HbA1c control as Whites (Figure 2).  In the stratified mixed model, after 
adjusting for confounders, a 10% increased OHA adherence was associated with 0.08% lower HbA1c values in 
African-American and 0.05% lower HbA1c values in Whites. Similar findings have been reported from various 
studies.30-31  In the combined analysis, the significant interaction (-0.26, p<0.0001) between OHA adherence and 
race suggested potentially differential adherence effects in black and white patients.  Although the racial difference 
in HbA1c control may or may not be biologically and genetically independent,32-33 our study identified a modifiable 
risk factor: OHA non-adherence.  It is a consistent finding with one study that found no evidence of racial difference 
Predictors African-American White  Combined Model  
N (observations) 834 (2,856) 3,142 (9,928) 3,976 (12,784)  
6-month PDC  -0.80 ± 0.10 -0.53 ± 0.04 -0.49 ± 0.05  
Age 0.02 ± 0.06 ^ 0.03 ± 0.02 ^ 0.02 ± 0.02 ^  
African-American (AA) -- -- -- -- 0.55 ± 0.06  
6-month PDC *AA -- -- -- -- -0.26 ±0.11  
Non-commercial  insurance -0.23 ± 0.12 -0.26 ± 0.06 -0.19  ±0.06  
Female gender 0.06 ± 0.13 ^ -0.24 ± 0.04 -0.21 ± 0.04  
Duration of OHA treatment  -0.10 ± 0.06 ^ 0.15 ± 0.30 0.12 ± 0.03  
Number of A1C test -0.10 ± 0.02 -0.04 ± 0.01 -0.06 ± 0.01  
Number of OHA medication -0.38 ± 0.06 -0.17 ± 0.02 -0.24 ± 0.02  
OHA class        
Biguanides Only -1.25 ± 0.15 -0.80 ± 0.05 -0.95 ± 0.05  
Sulfonylurea Only -0.51 ± 0.16   -0.23 ± 0.07   -0.34 ± 0.07    
Thiazolidinedione Only -1.23 ± 0.27 -0.87 ± 0.09 -1.01 ± 0.10  
Other -1.47 ± 0.58 -0.68 ± 0.20 -0.90 ± 0.22  
Multiple Classes -- -- -- -- -- --  
Metropolitan Status -1.16 ± 0.80 ^ -0.06 ± 0.07 ^ -0.05 ±0.09 ^  
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In addition to OHA adherence, other patient behaviors such as physical activity, diet habits, education level, income, 
physical facility availability and soft drink consumption may also affect patient HbA1c control.  However, this 
information usually is not available in an EMR/HIE system. In order to overcome this limitation, we linked the 
publically accessible USAD health environmental data. However, most environmental factors (which were only 
available at the county level) showed no significant association with patient HbA1c control, and very few showed 
marginal association in the analyses.  Although county-level health profiles may capture important information, it 
may not provide sufficient information for the individual patients in our study. The reason might be a lack of 
variation in these measures because 90% of subjects were Indiana metropolitan residents.  
 
Effective interventions in medication adherence combine convenient care, information, reminders, self-monitoring, 
and counseling.37 The emergence of HIE/HIT offers new approaches.  CDSS’s provide faster and better clinical 
decisions and do reduce clinical errors caused by human limitations in processing data.38-39  A CDSS embedded in 
an HIE can easily and programmatically establish a data-driven assessment of medication adherence and identify 
patients who are not adhering to their medication.  Recent success stories promoting adherence by HIT included 
Community Care of North Carolina (CCNC), Geisinger Health System, and Group Health Cooperative. Collecting 
patient medication history from multiple resources and assessing patient adherence status are the core components 
for each of these HIT interventions.12 Our study confirmed that data-driven measures of medication adherence and 
predicted risk factors using aggregated HIE data are associated with objective clinical outcomes in patients with type 
2 diabetes.  The evidence-based knowledge may therefore prove to be useful and should be introduced into routine 
clinical practices through CDSS’s.  
 
Limitations 
 
This study is an observational study, not an experiment. We should keep in mind that findings from this study 
demonstrated associations (not causation) between OHA adherence and HbA1c levels, as well as associations (not 
causation) between predictors and OHA adherence. This study was based on medication and HbA1c laboratory data 
that were captured from an operation HIE.  Although we intended to maximally utilize patient data, we were unable 
to report on patients who had no records of an OHA dispensing event or HbA1c test.  In addition, the patient data 
might be incomplete if a patient switched to an insurance plan which does not participate in our HIE.  
 
 
CONCLUSIONS 
 
Using longitudinal data from the Indiana Network of Patient Care (INPC), we identified significant differences in 
OHA adherence and HbA1c control between African-Americans and Whites in the Indiana population.  Increased 
OHA adherence was significantly correlated with better glycemic control for both racial groups, and potentially 
eliminated the gap of HbA1c levels.  Findings from this study support establishing HIE/HIT interventions that assess 
patient medication adherence using data captured from different data resources in an HIE.  In addition, risk factors 
for OHA non-adherence identified from this study provide necessary knowledge to further establish more predictive, 
patient-specific, tailored, and team-based CDSS interventions regarding medication adherence, with continued 
efforts from the Central Indiana Beacon Community. 
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